Institut National De La Sante Et De La Recherche Medicale

Institut Gustave Roussy

Inserm (institut National De La Sante Et De La Recherche Medicale)

Eric Vivier

Michel Pierres

Myriam Baratin

Alessandro Moretta

Laurence Zitvogel

Lucia Olcese

Frédéric Vely

Elena Tomasello

Disclosed are monoclonal antibodies that specifically bind to the B7 family member B7H6, including antibodies capable of inhibiting the interaction of B7H6 with NKp30. Also disclosed are anti-B7H6 antibody-drug conjugates comprising an anti-B7H6 monoclonal antibody conjugated to a therapeutic agent. The anti-B7H6 antibodies and antibody-drug conjugates are useful in methods for exerting therapeutic effects against B7H6-expressing cells, as well as in diagnostic methods for the detection of B7H6 or B7H6-expressing cells.

Monoclonal antibodies that bind B7H6 and uses thereof

The present invention relates to a method of predicting or monitoring the sensitivity of a subject having a tumor to a chemotherapy, a method of selecting an appropriate chemotherapeutic treatment of cancer, a method of screening or identifying a compound suitable for improving the treatment of a cancer, and corresponding kits. The method of predicting or monitoring the sensitivity of a subject having a tumor to a chemotherapy typically comprises a step a) of determining, in a biological sample from said subject, the presence, absence or expression level of at least one of a soluble B7H6 (sB7H6 or sB7-H6) and a soluble MIC (sMIC) and, when the expression level is determined, a step b) of comparing said expression level to a reference expression level, thereby assessing or monitoring whether the subject having a tumor is responsive or resistant to the chemotherapy.

Methods of treating gastrointestinal sarcoma patients depending on their sB7H6 serum level

The invention concerns novel means for diagnosing, preventing, compensating, treating an abnormal or unwanted functioning of KAR receptors (Killer cell Activatory Receptor), counterparts of non-inhibiting KIR receptors (Keller cell Inhibitory Receptors) of the immunoglobulin or lectin type. The invention concerns in particular, novel KARAP (KAR-Associated Proteins) polypeptides and their biological applications. A KARAP polypeptide is naturally associated with a KAR receptor, and in the absence of such a KARAP, said KAR receptor is naturally incapable of transducing an activating signal that can be detected. The application also concerns methods for obtaining or identifying such KARAP polypeptides.

Polypeptides associated with activatory receptors and their biological applications

Growing community of inventors

Cassis, France

Eric Vivier